Drug Trial Radar · NCT05257798
A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Feb 28, 2022
Primary completion
Mar 21, 2023
Study completion Mar 21, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn if the study medicine (called PF-06823859) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: * Are between 18 to 45 years of age, inclusive, at the time of signing the Informed Consent Document (ICD). * Are Chinese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12 lead ECG (electrocardiogram). * Have a BMI (body mass index) of 19 to 27 kg/m2 (inclusive); and a total body weight \>50 kg (110 lb). All participants in this study will receive PF-06823859 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-06823859 will be given as an infusion directly into a vein. We will compare the experiences of people receiving PF-06823859 to those of people who do not. This will help us determine if PF-06823859 is safe and how it behaves inside the human body. Participants will take part in this study for up to 157 days. During this time, they will receive PF-06823859 or placebo and be observed for any effects.
Conditions
- Healthy
Interventions
IFN-β inhibitor treatmentDrug
PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
PlaceboOther
Placebo for PF-06823859, 0 mg/mL solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Serum Concentration(Cmax) for PF-06823859Time frame: Days 1 (pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Time at Which Cmax Occured (Tmax) for PF-06823859 in SerumTime frame: Days 1 (pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Area Under the Concentration-time Profile From Time Zero to 14 Days (336 Hours) Post-dose (AUC14day) for PF-06823859 in SerumTime frame: Days 1 (pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Area Under the Concentration-time Profile From Time Zero to 28 Days (672 Hours) Post-dose (AUC28day) for PF-06823859 in SerumTime frame: Days 1(pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Area Under the Serum Concentration-time Profile From Time Zero Extrapolated to Infinite Time(AUCinf) for PF-06823859 in Serum.Time frame: Days 1(pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Terminal Half-life (t1/2) for PF-06823859 in Serum.Time frame: Days 1(pre-dose, 1, 2, 6, 12 hours post dose), 2,3,5,15,29,43,57,71,100,127 and 157.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug/Day 1 to Day 157
- Number of Participants With Pre-Specified Categorization for Vital Signs (Diastolic Blood Pressure)Time frame: Days 1 (pre-dose),5,29,57,100,127 and 157.
- Number of Participants With Pre-Specified Categorization for Vital Signs (Systolic Blood Pressure)Time frame: Days 1 (pre-dose),5,29,57,100,127 and 157.
- Number of Participants With Pre-Specified Categorization (Maximum Change From Baseline) for ECG DataTime frame: Days -1, 5,29,57,100,127 and 157.
- Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality).Time frame: Days -1, 2, 5,8,15,29,57,100,127 and 157.
- Number of Participants With Viral InfectionsTime frame: From Screening up to Day157
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.